WO2024086708A3 - Compositions and methods for preventing cardiomyopathy - Google Patents

Compositions and methods for preventing cardiomyopathy Download PDF

Info

Publication number
WO2024086708A3
WO2024086708A3 PCT/US2023/077291 US2023077291W WO2024086708A3 WO 2024086708 A3 WO2024086708 A3 WO 2024086708A3 US 2023077291 W US2023077291 W US 2023077291W WO 2024086708 A3 WO2024086708 A3 WO 2024086708A3
Authority
WO
WIPO (PCT)
Prior art keywords
usp30
methods
disclosed
small molecule
cancer
Prior art date
Application number
PCT/US2023/077291
Other languages
French (fr)
Other versions
WO2024086708A2 (en
Inventor
Judith KRIGMAN
Nuo SUN
Mingchong YANG
Ruohan ZHANG
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of WO2024086708A2 publication Critical patent/WO2024086708A2/en
Publication of WO2024086708A3 publication Critical patent/WO2024086708A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are small molecule inhibitors of USP30 and their use in treating, ameliorating and/or preventing cardiomyopathy. Additionally, disclosed herein are methods of inhibiting the USP30 pathway and activity comprising contacting a cell expressing USP30 or administering to a subject in need of USP30 inhibition, any of the small molecule USP30 inhibitors disclosed herein. Also disclosed are chemotherapeutic regimens for the treatment of cancer that include a small molecule USP30 inhibitor in combination with chemotherapeutic agent to treat the cancer, as well as methods of treating cancer using these regimens.
PCT/US2023/077291 2022-10-19 2023-10-19 Compositions and methods for preventing cardiomyopathy WO2024086708A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263417609P 2022-10-19 2022-10-19
US63/417,609 2022-10-19

Publications (2)

Publication Number Publication Date
WO2024086708A2 WO2024086708A2 (en) 2024-04-25
WO2024086708A3 true WO2024086708A3 (en) 2024-05-30

Family

ID=90738547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077291 WO2024086708A2 (en) 2022-10-19 2023-10-19 Compositions and methods for preventing cardiomyopathy

Country Status (1)

Country Link
WO (1) WO2024086708A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071073A1 (en) * 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
US20200261469A1 (en) * 2017-10-17 2020-08-20 Albert Einstein College Of Medicine Mitofusin activators and uses thereof
US10968172B2 (en) * 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
US20220251041A1 (en) * 2015-03-30 2022-08-11 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
US20220315531A1 (en) * 2019-09-11 2022-10-06 Vincere Biosciences, Inc. Usp30 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220251041A1 (en) * 2015-03-30 2022-08-11 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10968172B2 (en) * 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
WO2019071073A1 (en) * 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
US20200261469A1 (en) * 2017-10-17 2020-08-20 Albert Einstein College Of Medicine Mitofusin activators and uses thereof
US20220315531A1 (en) * 2019-09-11 2022-10-06 Vincere Biosciences, Inc. Usp30 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BHARATH LEENA P., ROCKHOLD JACK DONATO, CONWAY RACHEL: "Selective Autophagy in Hyperglycemia-Induced Microvascular and Macrovascular Diseases", CELLS, MDPI AG, vol. 10, no. 8, pages 2114, XP093177503, ISSN: 2073-4409, DOI: 10.3390/cells10082114 *

Also Published As

Publication number Publication date
WO2024086708A2 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
Morini et al. The role of the thiol N-acetylcysteine in the prevention of tumor invasion and angiogenesis
EP4327882A3 (en) Enpp1 inhibitors and their use for the treatment of cancer
MX2016008201A (en) Cancer treatment using combinations of erk and raf inhibitors.
CR20220584A (en) Fused tricyclic kras inhibitors
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
CR20210563A (en) Compounds and methods for the treatment of covid-19
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
WO2007056244A3 (en) Methods of using saha and erlotinib for treating cancer
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
WO2018102687A3 (en) Combination therapy for treating cancer
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
WO2007056162A3 (en) Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2021014175A (en) Treatment of hair loss disorders with deuterated jak inhibitors.
MX2021005240A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents.
Ogawa et al. New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms
ES2185323T3 (en) USE OF ERYTHROPOIETIN IN THE TREATMENT OF MULTIPLE MYELOMA.
BRPI0413410A (en) coadministration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
MX2021013271A (en) Rank pathway inhibitors in combination with cdk inhibitors.
WO2020159171A3 (en) Composition comprising streptonigrin and anticancer agent for preventing or treating colorectal cancer
WO2024086708A3 (en) Compositions and methods for preventing cardiomyopathy
MX2023003332A (en) Line-1 inhibitors to treat disease.
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
WO2019241641A3 (en) Cancer treatment methods
WO2023192491A3 (en) Nucleoside line-1 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23880797

Country of ref document: EP

Kind code of ref document: A2